Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Amylyx Pharmaceuticals, Inc. (AMLX)
Company Research
Source: Yahoo! Finance
of recruitment expected in 2025, with topline data anticipated in first half of 2026 Completed a public offering of common stock with net proceeds of approximately $65.5 million, extending the company's cash runway through the end of 2026 Management to host conference call and webcast today at 8:00 a.m. Eastern Time CAMBRIDGE, Mass., March 04, 2025 BUSINESS WIRE Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) ("Amylyx" or the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2024. "We made significant progress in 2024 across our pipeline, setting the stage for important milestones in the year ahead in orphan markets with high unmet need. We advanced our lead investigational asset avexitide into a pivotal Phase 3 trial and expect topline results in the first half of 2026. This year, we anticipate Week 48 data from our AMX0035 program in Wolfram syndrome, interim analysis data from our AMX0035 program in PSP, and early cohort data fr
Show less
Read more
Impact Snapshot
Event Time:
AMLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMLX alerts
High impacting Amylyx Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMLX
News
- Is Early AMX0114 Safety Data Altering The Investment Case For Amylyx Pharmaceuticals (AMLX)? [Yahoo! Finance]Yahoo! Finance
- Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA TrialBusiness Wire
- HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSPR Newswire
- Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLXBusiness Wire
- Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Amylyx Pharmaceuticals, Inc. – AMLXBusiness Wire
AMLX
Earnings
- 11/6/25 - Beat
AMLX
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/17/25 - Form SCHEDULE
- AMLX's page on the SEC website